Educational Objectives

The PHA Preceptorship Program is designed to improve competence, performance and patient care practices by instructing front-line clinicians in the highest quality of care for patients with PAH by combining didactic discourse and highly interactive case-based discussion. At the conclusion of this program, participants should be able to:

Define key pathophysiologic and epidemiologic components of PAH

Accurately diagnose patients through comprehensive screening and early recognition of symptoms

Evaluate the patient’s condition and prescribe optimal long-term management, including knowing when and how to treat and when to consult with colleagues at an established PAH center

Tailor comprehensive care for complex patient populations

Washington University School of Medicine designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™.

DIAMONDSUPPORTER

PLATINUMSUPPORTER

GOLDSUPPORTER

GOLDSUPPORTER

Actelion Pharmaceuticals US, Inc.

Gilead Sciences, Inc.

Bayer HealthCare

United Therapeutics Corporation

This is a program of the PHA Medical Education Fund, made possible through unrestricted educational grants from our supporters.

PHA ONLINE UNIVERSITY

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.